Course

Quality Improvement in RA: How Far Have We Come and How Far Must We Still Go?

0 out of 3 steps completed0%
0 Lessons

Quality Improvement in RA: How Far Have We Come and How Far Must We Still Go?

Learning Objectives

  1. Identify measures within the Physician Quality Reporting System (PQRS) that are most relevant to the treatment of patients with rheumatoid arthritis
  2. Explain key concepts such as quality improvement, meaningful use, and the Choosing Wisely campaign
  3. Determine the current status of your specific practice regarding adherence to PQRS and meaningful use reporting requirements
  4. Evaluate opportunities to customize your practice’s electronic health records to help improve adherence to quality indicators and potentially ease reporting burdens

Disclosure

It is the policy of the Rheumatology Nurses Society (RNS) that the education presented within RNS.provided activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, RNS provides information that planners, teachers, authors, developers, and activity managers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Any relationships that an individual may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.

Relationships are abbreviated as follows:

E, Educational planning committee;
G, Grant/research support recipient;
A, Advisor/review panel member;
C, Consultant;
S, Stock shareholder;
SB, Speaker bureau;
PE, Promotional event talks;
H, Honoraria;
O, Other.

Sheree Carter, PhD, RN, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene, Antares, Amgen/A.

Jacqueline Fritz, RN, MSN, CNS, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: GlaxoSmithKline/A, Celgene, AbbVie/SB.

Elizabeth Kirchner, CNP, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content included in this educational activity.

Iris Zink, MSN, NP, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie/A,SB; Celgene/A; Antares/C: Bristol Myers-Squibb/SB.

Target Audience

The intended audience for this activity includes rheumatology nurses, rheumatology advanced practice nurses, and infusion nurses.

Content Direction

Scott Kober, MBA, CCMEP, Principal, MedCaseWriter, Inc. has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Freelancer

Anne Jacobson, MPH, CCMEP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Content Peer Reviewer

This newsletter was reviewed by Deanna Owens, MSN, RN. Ms. Owens has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene/A, SB; Antares/C; Janssen, AbbVie/SB.

Production Management

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC. has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Product Disclosure

This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.